New hope for rare cancers: targeted drug enters human trials
NCT ID NCT06378593
First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This study tests an experimental drug called 3HP-2827 in adults with advanced solid tumors that have specific FGFR2 gene changes. The goal is to find a safe dose and see if the drug can shrink tumors. About 130 participants will take the drug by mouth, and researchers will monitor side effects and how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS WITH FGFR2 ALTERATIONS, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact
-
ZhongShan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200123, China
Contact
Conditions
Explore the condition pages connected to this study.